Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Short Attack - Strategic Review

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Mar 09, 2023 10:43am

248 Views

Post# 35328069

Short Attack - Strategic Review

I think we are under a short attack // in combo with a hostile take over move.

Management needs to hire external consultants i.e. do "Strategic Review" formalized the bidding process so to maximize share value.

Otherwise, will we be robbed here...

Anyway, this lady is going to make money either way but would prefer a massive billion dollar homerun.

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?